Cefdinir (FK482), cefetamet (Ro 15-8074), CI-960, fleroxacin, lomefloxacin, and temafloxacin have potent activities against Neisseria gonorrhoeae. They were tested in a multilaboratory study to establish quality control guidelines. Quality control ranges for N. gonorrhoeae ATCC 49226 were determined by using multiple GC agar lots, three disk lots, and a number of test replicates consistent with the M23-T guidelines of the National Committee for Clinical Laboratory Standards. The MIC ranges included 2 to 4 log2 dilution steps. The recommended inhibition zone diameter ranges were generally 7 to 8 mm and included .91.3% of all recorded study results.
With the increasing prevalence of antimicrobial agentresistant strains of Neisseria gonorrhoeae (4), different strategies for epidemiologic control must be investigated. Also, more drugs have been introduced as options for the successful treatment of these difficult-to-treat strains, thus requiring standardized testing methods. The National Committee for Clinical Laboratory Standards (NCCLS) Gonococcus Working Group and subsequent independent investigators have identified numerous additional compounds that should be added to those that have already been approved for testing against N. gonorrhoeae. Those drugs listed in the NCCLS method tables are ceftriaxone, penicillin, spectinomycin, cefotaxime, cefoxitin, ceftazidime, tetracycline, cefuroxime, cefixime, cefotetan, ofloxacin, enoxacin, and temafloxacin (11, 12, (15) (16) (17) . This report summarizes the results submitted to the NCCLS from multilaboratory studies to establish MIC and disk quality control (QC) guidelines for cefdinir (FK482), cefetamet (Ro 15-8074), CI-960, fleroxacin, lomefloxacin, and temafloxacin by using the N. gonorrhoeae ATCC 49226 QC strain (11) . QC parameters for another related compound, ciprofloxacin, have also been reported (5). Each drug described in this report has demonstrated potent in vitro activity against gonococci (1, 3, (6) (7) (8) 10 The study design conformed to the guidelines presented in the NCCLS M23-T document (14) . Susceptibility (2) . Cefetamet MICs had a bimodal distribution. The actual cefetamet MIC probably was between the observed modes of 0.03 and 0.06 ,ug/ml (50 occurrences each). Furthermore, equal distributions were found at 0.015 and 0.12 ,ug/ml, requiring a four-dilution range (2) . All Therefore, a practical QC range of <0.001 to 0.002 ,ug/ml has been proposed. The MIC QC range for temafloxacin has been recently accepted by the NCCLS (16) .
The disk diffusion inhibition zone diameters for each drug tested in this multilaboratory study are presented in Table 2 . Data from one laboratory with median inhibition zone diameter results (for all drugs) that varied significantly from those of the participating laboratories were excluded from the analysis. Thus, a five-laboratory consensus (14) is reported, producing a total of 300 inhibition zone diameters per drug and per unique lot and 75 test results per drug for the common GC agar lot. The median statistical method was initially applied to determine the QC inhibition zone range of each antimicrobial agent (median range; Table 2 ) (14) . QC inhibition zone ranges produced by the median statistical method were quite narrow; e.g., only 74.3 to 89.3% of inhibition zones were within the range for all antimicrobial agents except cefetamet (for which 97.7% were in the range). This method (14) appears to be less applicable for some fastidious organism tests and media, for which interlaboratory or intermedium lot performance differences were greater than the intralaboratory variation. However, for some GC agar QC limits, >90% of disk test zones were within the calculated ranges (12) (cefetamet, this study).
Modification of the median range statistic (increase of inhibition zone from 1 to 3 mm) was necessary for cefdinir, CI-960, fleroxacin, lomefloxacin, and temafloxacin to ensure a proposed QC range with .90% reagent performance with the control strain. In contrast, if a more traditional 95 or 98% confidence limit were used, the QC inhibition zone diameter range would be so lenient as to produce meaningless QC limits. The inhibition zone diameter produced by the three disk lots for each antimicrobial agent did not differ significantly. Also, the common-lot median inhibition zone diameter did not vary by more than 1 mm from that observed for all unique lots ( Table 2) .
The proposed QC data for the six antimicrobial agents presented here expand the number of compounds against which N. gonorrhoeae strains can be reliably tested. Of the drugs tested, temafloxacin QC guidelines have been accepted by the NCCLS (17) . QC guidelines for the remaining compounds should be considered tentative until they are officially adopted or modified by national standardization groups. Among the drugs tested, cefetamet, fleroxacin, and temafloxacin have already been used as single-dose regimens to treat uncomplicated gonorrhea, with excellent clinical success reported (9, 13, 18) . 
